Yuhan Corp
000105
Company Profile
Business description
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.
Contact
74 Noryangjin-ro
Daebang-dong
Dongjak-gu
Seoul
KORT: +82 28280181
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
2,123
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.00 | 26.80 | 0.30% |
| CAC 40 | 8,157.82 | 69.50 | -0.84% |
| DAX 40 | 24,128.98 | 26.47 | -0.11% |
| Dow JONES (US) | 49,230.71 | 79.61 | -0.16% |
| FTSE 100 | 10,379.08 | 77.93 | -0.75% |
| HKSE | 26,016.21 | 38.14 | 0.15% |
| NASDAQ | 24,836.60 | 398.10 | 1.63% |
| Nikkei 225 | 60,839.04 | 1,122.86 | 1.88% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,165.08 | 56.68 | 0.80% |
| S&P/ASX 200 | 8,771.60 | 22.40 | 0.26% |
| SSE Composite Index | 4,085.88 | 5.98 | 0.15% |